Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
Rezo Therapeutics’ $78 Million Series A Financing
MBX Biosciences’ $115 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on the deal while WilmerHale advised Wellington Management. MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision...
Zenas BioPharma’s $118 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised lead investor Enavate Sciences and new investor Longitude Capital in the financing. Global pharmaceutical company Zenas BioPharma announced a $118...
DICE Therapeutics’ $345 Million Public Offering
Wilson Sonsini Goodrich & Rosati advised DICE Therapeutics on the deal. DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
Rivus Pharmaceuticals’ $132 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
Equillium’s Acquisition of Metacrine
Wilson Sonsini advised Metacrine on the deal. Equillium, Inc. and Metacrine Inc. announced that the two companies have entered into a definitive merger agreement pursuant to...
RayzeBio’s $160 Million Series D Financing
Wilson Sonsini advised RayzeBio on the deal. RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced a $160 million...
Metagenomi’s $175 Million Series B Financing
Fenwick & West and Wilson Sonsini Goodrich & Rosati advised Metagenomi on the deal while Gunderson Dettmer represented PFM Health Sciences. Metagenomi, a genetic medicines company...
ABL Bio’s License Agreement with SANOFI
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...
Ambagon Therapeutics’ $85 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Ambagon Therapeutics on the deal. Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced...
Adanate’s $30 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Adanate on the deal. Adanate, a biotech company focusing on therapies in oncology and immunology, recently raised $30 million in...
Sorriso Pharmaceuticals’ $31 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Sorriso Pharmaceuticals on the deal. Sorriso Pharmaceuticals, a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of...